Close

Anti-CEA (C2-45) h(CD28-41BB-CD3ζ) CAR, pCDCAR1 (CAR-MZ172)


All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The vector of anti-CEA chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target human CEA. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-CEA antibody linked to CD28 and 41BB and CD3ζ signaling domains. And the vector product was designed for the treatment of CEA positive cancers.

Specific Inquiry

  • Size:
  • Marker:
  • Form:
  Add to Cart

Details

  • Target
  • CEA
  • Targeting Cell Type
  • T cell
  • Targeting Diseases
  • CEA positive cancers
  • Generation
  • Third
  • Vector Name
  • pCDCAR1
  • Vector Length
  • ~8kb
  • Vector Type
  • Lentiviral
  • Receptor Construction
  • scFv-CD28-41BB-CD3ζ
  • Discription of Signaling Cassetes
  • CD28
    CD28 (Cluster of Differentiation 28) is one of the proteins expressed on T cells that provide co-stimulatory signals required for T cell activation and survival. CD28 is the receptor for CD80 (B7.1) and CD86 (B7.2) proteins which are expressed on antigen-presenting cells (APC). CD28 modulates the primary TCR/CD3ζ signal in a different fashion than the late costimulatory elements OX40 and 4-1BB. CD28 enhances the expression of downstream regulators that impact on T-cell proliferation, death, differentiation, and effector functions. CAR+ T cells containing the CD28 endodomain showed strikingly enhanced sustained T cell activation, growth, survival. And CD28 results in a brightly expressed, stable receptor as the transmembrane domain. Including CD28 costimulatory domains in CARs led to enhanced anti-malignancy efficacy.
    41BB
    CD137 (also known as 4-1BB) is a surface co-stimulatory glycoprotein originally described as present on activated T lymphocytes, which belongs to the tumor necrosis factor (TNF) receptor superfamily. It is expressed mainly on activated CD4+ and CD8+ T cells, and binds to a high-affinity ligand (4-1BBL) expressed on several antigen-presenting cells such as macrophages and activated B cells. On the basis of preclinical observation, this molecule can promote the persistence of antigen-specific and antigen-nonspecific chimeric antigen receptor T-cells to significantly increases antitumor activity.
    CD3ζ
    CD3ζ, also known as T-cell receptor zeta, which together with T-cell receptor and CD3γ, δ , ε chain, forms the TCR-CD3 complex. ζ was expressed independently from the complex. The zeta chain plays an important role in coupling antigen recognition to several intracellular signal-transduction pathways. CD3-zeta, which contains 3 ITAMs, is the most commonly used endodomain component of CARs. It transmits an activation signal to the T cell after antigen is bound. CD3-zeta may not provide a fully competent activation signal and additional co-stimulatory signaling is needed. For example, chimeric CD28 and OX40 can be used with CD3-zeta to transmit a proliferative/survival signal, or all three can be used together.

Target

  • Clone
  • C2-45
  • Host
  • Human
  • Target Species
  • Human
  • Gene Name
  • CEA
  • Synonyms
  • CEA; CD66e;

Customize Your CAR Products

Cannot find the desired product? Don't worry, just try our online CAR and CAR cell customizing system, which offers full options to meet all unique needs, including but not limited to conventional or unconventional CAR constructs, as well as a variety of vectors and cells. The customization process can be completed with just a few simple clicks, please feel free to try it out.
CAR and CAR Cell Customizing System
  • Published Data
CAR scFv data ELISA

Fig.3 Reactivity of C2-45(cIgG1) with purified CEA in ELISA.

CAR Construction : Latest CAR Construction

Fig.3 Reactivity of C2-45(cIgG1) with purified CEA in ELISA.

After washing, the antibodies bound to CEA were detected with
biotinylated goat anti-human IgG.

Huang, J., Shibaguchi, H., Zhao, J., Luo, N., Kuroki, M., Kinugasa, T., ... & Kuroki, M. (2006). IgG isotype conversion of a novel human anti-carcinoembryonic antigen antibody to increase its biological activity. Anticancer research, 26(2A), 1057-1063.

CAR scFv data FCM

Fig.4 Reactivity of C2-45(cIgG1) with CEA-expressing cells in flow cytometric analysis.

CAR Construction : Latest CAR Construction

Fig.4 Reactivity of C2-45(cIgG1) with CEA-expressing cells in flow cytometric analysis.

The cells used were incubated with C2-45(cIgG1),C2-45(IgG4) or control human IgG for 1 hour on ice. After washing, the cells were stained with fluorescein-conjugated rabbit anti-human IgG.

Huang, J., Shibaguchi, H., Zhao, J., Luo, N., Kuroki, M., Kinugasa, T., ... & Kuroki, M. (2006). IgG isotype conversion of a novel human anti-carcinoembryonic antigen antibody to increase its biological activity. Anticancer research, 26(2A), 1057-1063.

CAR scFv data FCM

Fig.5 Binding of C2-45(IgG1) with CEA-expressing cells in flow cytometric analysis.

CAR Construction : Latest CAR Construction

Fig.5 Binding of C2-45(IgG1) with CEA-expressing cells in flow cytometric analysis.

All measurements were performed in triplicate.

Huang, J., Shibaguchi, H., Kuroki, M., Hirose, Y., Yamada, H., Zhao, J., ... & Kuroki, M. (2006). Subclass Conversion from IgG4 to IgG1 of a Novel Human Anti-CEA Antibody for Increasing Its Biological Activity. Japan Journal of Molecular Tumor Marker Research, 21, 53-54.

CAR scFv data FCM

Fig.6 Specificity of anti-CEA mAb-mediated targeting.

CAR Construction : Latest CAR Construction

Fig.6 Specificity of anti-CEA mAb-mediated targeting.

Transduction efficiency of CEACAM-transfected CHO cells evaluated by flow cytometry.

Tanaka, T., Huang, J., Hirai, S., Kuroki, M., Kuroki, M., Watanabe, N., ... & Hamada, H. (2006). Carcinoembryonic Antigen–Targeted Selective Gene Therapy for Gastric Cancer through FZ33 Fiber-Modified Adenovirus Vectors. Clinical cancer research, 12(12), 3803-3813.

CAR scFv data Inhibit

Fig.7 Competitive inhibition assay. CEA-CHO cells were transduced with Ax3CAZ3-FZ33 at 1,000 VP/cell after preincubation with C2-45.

CAR Construction : Latest CAR Construction

Fig.7 Competitive inhibition assay. CEA-CHO cells were transduced with Ax3CAZ3-FZ33 at 1,000 VP/cell after preincubation with C2-45.

All measurements were performed in triplicate.

Tanaka, T., Huang, J., Hirai, S., Kuroki, M., Kuroki, M., Watanabe, N., ... & Hamada, H. (2006). Carcinoembryonic Antigen–Targeted Selective Gene Therapy for Gastric Cancer through FZ33 Fiber-Modified Adenovirus Vectors. Clinical cancer research, 12(12), 3803-3813.

CAR scFv data FCM

Fig.8 The L45scFv-CIR expression on human T-cells. Primary human T-cells (5x106 cells) were transfected with 2 Ìg of the L45scFv-CIR gene.

CAR Construction : Latest CAR Construction

Fig.8 The L45scFv-CIR expression on human T-cells. Primary human T-cells (5x106 cells) were transfected with 2 Ìg of the L45scFv-CIR gene.

Transfectants (1x106 cells) were stained with 1 Ìg/ml of APC-labeled BSA or CEA for 1 h at 4ÆC 24 hrs after nucleofection.

Shibaguchi, H., Luo, N. X., Kuroki, M., Zhao, J., Huang, J., Hachimine, K., ... & Kuroki, M. (2006). A fully human chimeric immune receptor for retargeting T-cells to CEA-expressing tumor cells. Anticancer research, 26(6A), 4067-4072.

CAR scFv data IHC

Fig.9 Binding of L45 scFv-CIR transfected primary human T-cells to CEA-expressing tumor cells.

CAR Construction : Latest CAR Construction

Fig.9 Binding of L45 scFv-CIR transfected primary human T-cells to CEA-expressing tumor cells.

The CEA expressing MKN-45 cells were mixed with parental T-cells or transfectants at the ratio of 1:5 and incubated for rossette formation for 1 h at 37C.

Shibaguchi, H., Luo, N. X., Kuroki, M., Zhao, J., Huang, J., Hachimine, K., ... & Kuroki, M. (2006). A fully human chimeric immune receptor for retargeting T-cells to CEA-expressing tumor cells. Anticancer research, 26(6A), 4067-4072.

CAR scFv data ELISA

Fig.10 The CEA binding activity of serially diluted 45scFvLCHα was evaluated by ELISA.

CAR Construction : Latest CAR Construction

Fig.10 The CEA binding activity of serially diluted 45scFvLCHα was evaluated by ELISA.

Antigen binding activity of isolated 45scFvLCHα.

Zhao, J., Kuroki, M., Shibaguchi, H., Wang, L., Huo, Q., Takami, N., ... & Kuroki, M. (2008). Recombinant human monoclonal igA antibody against CEA to recruit neutrophils to CEA-expressing cells. Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics, 17(5), 217-222.

Complete CAR data WB

Fig.1 The analysis of CAR protein expression.

CAR Construction : C2-45 scFv-28ζ Latest CAR Construction

Fig.1 The analysis of CAR protein expression.

Lysates were prepared from wild-type and CAR-expressing Jurkat cells, and immunoreactive bands were detected by Western blotting using an anti-CD3ζ.

Shirasu, N., Shibaguci, H., Kuroki, M., Yamada, H., & Kuroki, M. (2010). Construction and molecular characterization of human chimeric T-cell antigen receptors specific for carcinoembryonic antigen. Anticancer research, 30(7), 2731-2738.

Complete CAR data FuncS

Fig.2 The formation of the signaling clusters in CAR-expressing cells by antigen stimulation.

CAR Construction : C2-45 scFv-28ζ Latest CAR Construction

Fig.2 The formation of the signaling clusters in CAR-expressing cells by antigen stimulation.

Jurkat cells co-expressing ZAP-70-AcGFP and CAR45-28ζ were plated onto a CEA-coated coverslips, fixed and stained with Alexa-labelled anti-CD3ζ and anti-myc antibodies.

Shirasu, N., Shibaguci, H., Kuroki, M., Yamada, H., & Kuroki, M. (2010). Construction and molecular characterization of human chimeric T-cell antigen receptors specific for carcinoembryonic antigen. Anticancer research, 30(7), 2731-2738.

More Published Data More Published Data

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-CEA (C2-45) h(CD28-41BB-CD3ζ) CAR, pCDCAR1 (CAR-MZ172). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.